Advanced Search:
Equity Index

NYKD.OL - NYKODE THERAPEUTIC

kr13.83  -0.23 (-1.64%)

Updated: 08:41 May 8, 2024 EST

Next Session's AI Forecast

95.64%

Avg. Accuracy (AI)

kr14.06

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

kr13.49

NYKODE THERAPEUTIC's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

NYKODE THERAPEUTIC - HISTORICAL DATA 6M

  • Last price

    kr13.83

  • Daily change

    kr-0.23

  • Previous Close

    kr14.06

  • Last Updated

    08:41 May 8, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.41 -0.21 -0.43 -0.24 -0.26

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
2.06 1.89 2.59 2.7 2.48

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 58.33% 70.39% 14.54%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
13.88 3.27% 13.44 -2.04% 13.72 -19.63% 17.07

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.25 74.36 1.67 55.56

NYKODE THERAPEUTIC Technical Analysis News

NYKODE THERAPEUTIC

Oslo Research Park
Gaustadalleen 21
Oslo 0349
Norway
47 22 95 81 93
https://nykode.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 171
Description

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

Corporate Governance

Nykode Therapeutics AS’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

NYKODE THERAPEUTIC'S HOLDERS RANK

List of holders with stock participation in NYKODE THERAPEUTIC.

Holder Rank Holder Shares Date Reported % Out Value